Put Meds for Alzheimer Dementia in Perspective

July 2025

About 7 million people in the US age 65 years and older have Alzheimer dementia...and it’s expected to double by 2050.

Help put meds for Alzheimer disease (AD) in perspective.

Anti-amyloid monoclonal antibodies donanemab (Kisunla) and lecanemab (Leqembi) are only for mild cognitive impairment or mild dementia stages of AD...with amyloid beta plaques confirmed on brain imaging.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Rumor vs Truth Shed Light on Sunscreen Rumors
Education and Training Clarify Absolute and Relative Risk for Learners
Restless Legs Stay in Step With Treatments for Restless Legs Syndrome
Med Safety Expect Questions About Cetirizine and Phenazopyridine Safety
Practice Keep Noncontrolled Med Diversion on Your Radar
Allergic Reactions Help Patients With Alpha-Gal Syndrome Avoid Reactions
Alzheimer Disease Put Meds for Alzheimer Dementia in Perspective
OTC Products Prepare for Ivermectin to Be Sold OTC in Some States

Put Meds for Alzheimer Dementia in Perspective

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents